Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 2:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 2
3 (100.0%)Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Rectal Cancer (LARC)
- Interventions
- Drug: Total neoadjuvant therapy (TNT)
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- brenner baruch
- Target Recruit Count
- 134
- Registration Number
- NCT06940388
- Locations
- 🇩🇪
Johannes Gutenberg-University Clinic, Mainz, Germany 1.Dept. Medicine, Prof. Peter R. Galle, Mainz, Germany
🇮🇱Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
Trial of Nivolumab and Cetuximab After Chemoradiation in Esophageal Squamous Cell Carcinoma Patients.
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Baruch Brenner
- Target Recruit Count
- 31
- Registration Number
- NCT04229459
- Locations
- 🇮🇱
Rabin Medical Center, Petach Tikva, Israel
Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients
Phase 2
Recruiting
- Conditions
- Rectal Cancer
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Baruch Brenner
- Target Recruit Count
- 29
- Registration Number
- NCT03921684
- Locations
- 🇮🇱
Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel
News
No news found